论文信息 - LBA43 Spartalizumab plus dabrafenib and trametinib (Sparta-DabTram) in patients (pts) with previously untreated BRAF V600–mutant unresectable or metastatic melanoma: Results from the randomized part 3 of the phase III COMBI-i trial - 字舞流文

LBA43 Spartalizumab plus dabrafenib and trametinib (Sparta-DabTram) in patients (pts) with previously untreated BRAF V600–mutant unresectable or metastatic melanoma: Results from the randomized part 3 of the phase III COMBI-i trial

D. Schadendorf | K. Flaherty | P. Ascierto | R. Dummer | A. Ribas | H. Tawbi | M. Mandalà | P. Rutkowski | G. Long | P. Lorigan | P. Nathan | P. Ferrucci | C. Dutriaux | J. C. Brase | E. Gasal | T. Haas | S. Green | O. Leonov | C. Robert | Aisha Masood